Clinical Trial Details
— Status: Terminated
Administrative data
NCT number |
NCT05461014 |
Other study ID # |
STUDY21100037 |
Secondary ID |
|
Status |
Terminated |
Phase |
N/A
|
First received |
|
Last updated |
|
Start date |
July 30, 2022 |
Est. completion date |
March 8, 2023 |
Study information
Verified date |
June 2023 |
Source |
University of Pittsburgh |
Contact |
n/a |
Is FDA regulated |
No |
Health authority |
|
Study type |
Interventional
|
Clinical Trial Summary
Evaluate the feasibility and acceptability of adapted coached RxWell for patients ages 16-25.
Adapt and beta test the modified RxWell product to include chronic disease management and
transition readiness. Evaluate RxWell usage and its impact to the TRAQ questionnaire over
time.
Description:
Baseline TRAQ and PHQ-4 scores will be obtained from the patient as part of routine care
during annual visits or as a screening tool after consent to determine eligibility. If the
patient is recruited from a visit other than the annual visit, the TRAQ and PHQ4 will be
completed to determine eligibility after consent. If eligible, the participant will complete
the IBD self-efficacy scale, GAD7, and PHQ8, and will be provided with an access code to
download RxWell and will be paired with a UPMC digital health coach who will guide the person
through the sessions and text within the app to help give them the tools needed to actively
cope with anxiety and/or depression. The adapted version of RxWell includes the same RxWell
content/techniques but the coaching model within the adapted version has increased
responsibilities of the coach, encouraging the development of necessary transition knowledge
and skills for the patient. Coaches in this version will also participate in training about
how best to interact with IBD patients regarding their chronic illness, transitions to adult
physician, and care management. These coaches will be supervised by a licensed UPMC mental
health clinician. The coaches will be informed of the reason for each user's access to the
dCBI, TRAQ or PHQ score or both and will interact with the user accordingly. Participants
will be asked to complete all study measures (TRAQ, PHQ8, IBD Self-Efficacy, and GAD7) at all
time points, baseline, 3 and 6 months.
The user will have access to the app and coach for six months after they have consented. Each
technique that is used during those six months will be stored in the practice-again section
and available to the participant for use during the study. After six months, participants
will no longer have access to the app and will be informed about this change. Participants
are informed when they sign up for this app that is not a crisis management tool. There is a
risk escalation protocol in place at UPMC if the content of patient's messaging to coaches is
alarming.
A randomly selected group of patients who consent to this study and engage with the app,
meaning completing 3 or more techniques and/ or actively engaged with the coach, will
participate in qualitative interviews to determine how to best implement disease
self-management tools within the digital behavioral tool. Every third participant who
consents and meets the engagement criteria will be contacted to complete the qualitative
interview.
All participants will also be asked to complete quantitative assessments at baseline and
again 3 and 6 months later.